Vivlipeg

Vivlipeg (Pegfilgrastim) is a long-acting biosimilar used to support white blood cell recovery after chemotherapy. It belongs to the colony-stimulating factor class and is administered subcutaneously. This medication helps reduce infection risk during cancer treatment.

Vivlipeg is commonly used to shorten the duration of neutropenia and reduce the incidence of infection in patients receiving myelosuppressive chemotherapy. It may also be prescribed for stem cell mobilization prior to transplantation. People often ask, what is Pegfilgrastim used for in cancer care and how does it support immune function during treatment.

After administration, Vivlipeg works by stimulating the bone marrow to produce more white blood cells, particularly neutrophils. Patients may notice improved energy levels as their blood counts recover. Some individuals report mild bone or muscle discomfort as the body responds to the medication.

Vivlipeg should be handled with care and stored according to the manufacturer’s instructions to maintain potency. Patients with a history of sickle cell disorders should use this medication cautiously. Always inform your healthcare provider about current medications and health conditions before starting treatment.

Certain chemotherapy agents may interact with Vivlipeg, potentially affecting its effectiveness. Medications that suppress the immune system, such as corticosteroids, can reduce the drug’s intended action. Alcohol and other substances may also influence how the body responds to treatment.